Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 202 participants.

Also called NCT02388061

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 202 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02388061
Other papers using this trial's data
  • Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke The New England journal of medicine, 2018-04-26 DOI, PubMed 29694815
  • Tenecteplase versus alteplase before endovascular thrombectomy (EXTEND-IA TNK): A multicenter, randomized, controlled study International journal of stroke : official journal of the International Stroke Society, 2018-04 DOI, PubMed 28952914

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, New Zealand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02388061. Randomized; no masking; primary purpose treatment. Start 2015-03-23 (actual); primary completion 2017-10-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke
Acronym
EXTEND-IA TNK
Intervention (Drug)
Tenecteplase
Intervention (Drug)
Tissue Plasminogen Activator
Lead sponsor
Neuroscience Trials Australia (class: other)
Collaborator
The Florey Institute of Neuroscience and Mental Health (class: other)

Record details

Record id
cardio:ct-nct02388061
Content hash
f6acee7b1e0e141add12ee174f5c33b59026bf2604bc2d27a7168678b7c3047f